Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics, Plc amends its registration statement (File No. 333-297257) solely to file certain exhibits. The amendment attaches amended Articles of Association, deposit agreement documents for American Depositary Shares, forms of warrants (including Pre-Funded, Series H, I, and J), the Securities Purchase Agreement dated May 20, 2026 and its June 23, 2026 amendment, and related legal opinions and consents. The filing is signed by Abizer Gaslightwala as President and CEO on July 8, 2026.
Akari Therapeutics reported results of its June 30, 2026 Annual General Meeting. Shareholders approved the 2025 financial statements, most director re-elections, and the appointment and remuneration of BDO USA, P.C. and HaysMac LLP as auditors.
Shareholders also approved several equity-related items, including issuances under an ELOC Purchase Agreement, warrants and placement agent American Depositary Shares tied to May 20, 2026 securities and placement agent agreements, and a potential private placement that could result in a change of control. They authorized directors to allot shares up to an aggregate nominal amount of USD 20,000 through June 30, 2031 and passed a related special resolution allowing certain cash issuances without pre-emption rights.
Director James Neal was not re-elected and left the Board at the meeting’s conclusion. Following this, Dr. Ray Prudo joined the Audit Committee and Robert Bazemore became Chair of the Compensation Committee.
Akari Therapeutics, Plc is registering for resale 5,999,999 ADSs, representing 479,999,920,000 ordinary shares, for sale by the selling shareholders. This registration covers ADSs issued in a May 2026 private placement and ADSs issuable on exercise of several warrant series and pre-funded warrants. Each ADS represents 80,000 ordinary shares. The resale is by selling shareholders; Akari will not receive proceeds from those resales, although the company may receive proceeds if the registered warrants are exercised for cash.
The prospectus lists the selling shareholders, discloses a 4.99% or 9.99% beneficial ownership limitation on warrant exercises, and states the company had 140,032,769,533 ordinary shares outstanding as of June 30, 2026. The ADSs are listed on Nasdaq under the symbol AKTX and the prospectus includes customary risk factors about development-stage oncology operations, material weaknesses in internal control, and capital needs.
Akari Therapeutics, Plc reported an amendment to its securities purchase agreement with certain investors for a previously announced private placement of American Depository Shares (ADSs) and related warrants. The amendment combines the originally planned second and third funding closings into a single consolidated closing.
The private placement covers 1,470,588 unregistered ADSs, or prefunded warrants to purchase ADSs, each ADS representing 80,000 ordinary shares, together with Series H, Series I and Series J warrants. On the June 26, 2026 combined closing date, Akari issued the remaining 980,395 ADSs or prefunded warrants due under the agreement.
Delivery of the Series H, Series I and Series J warrants to investors remains contingent on receiving shareholder approval at Akari’s annual general meeting scheduled for June 30, 2026. Other than changing the closing schedule, the amendment leaves all other purchase agreement terms unchanged.
Akari Therapeutics is registering up to 2,500,000 American Depositary Shares (ADSs), representing 200,000,000,000 ordinary shares, for resale by White Lion Capital LLC. These ADSs back a $25 million equity purchase facility that Akari may tap at its discretion over a 36‑month period.
The registration includes 6,361 commitment ADSs that may be issued as consideration if Akari does not draw at least $625,000 from the facility within 180 days of effectiveness. Akari will not receive proceeds from White Lion’s resales, but will receive cash when it sells ordinary shares to White Lion under the Purchase Agreement. If all 2,500,000 ADSs are issued and sold, total ordinary shares outstanding would rise from 140,032,769,533 to 340,032,769,533, creating significant potential dilution and resale overhang for existing holders.
Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.
Akari Therapeutics Plc interim CFO Farag Kameel D. received share awards in the form of American Depositary Shares (ADSs) representing ordinary shares. On June 24, 2026, multiple grant/award transactions (code A) increased his direct ADS holdings to 20,452 shares.
A footnote explains these ADS-related awards represent restricted stock units (RSUs), with each RSU giving the right to receive 80,000 ordinary shares. The RSUs vested in full on June 24, 2026, indicating these grants are compensation-related rather than open‑market purchases.
Akari Therapeutics CEO Abizer Gaslightwala reported new stock option awards. On April 1, 2026 he was granted options over 15,563 American Depositary Shares at an exercise price of $14.63 per ADS and options over 5,500 ADS at $4.64 per ADS. Each ADS represents 80,000 ordinary shares. These awards were compensation-related grants rather than open-market share purchases or sales.
Akari Therapeutics, Plc. ownership disclosure: MMCAP International Inc. SPC and MM Asset Management Inc. report beneficial ownership of 8,000,000,000 Ordinary Shares, representing 8.0% of the class. The position represents 100,000 American Depositary Shares, each convertible into 80,000 Ordinary Shares, with the percent calculated on a partially‑diluted basis using 91,567,009,533 Ordinary Shares outstanding as of March 31, 2026 per the issuer's 10-Q. Both filers report shared voting power of 8,000,000,000 and shared dispositive power of 8,000,000,000.
Akari Therapeutics, Plc is asking shareholders to vote at its June 30, 2026 annual general meeting on 18 resolutions covering financial reports, pay, board elections, auditors and major share issuance authorities.
Shareholders will vote on receiving the 2025 statutory accounts, the U.K. directors’ remuneration report and a revised three‑year remuneration policy, plus a non‑binding “say‑on‑pay” for named executive officers. The company proposes re‑electing six Class A directors and ratifying BDO USA, P.C. as independent registered public accounting firm, alongside re‑appointing HaysMac LLP as U.K. statutory auditor.
Several capital resolutions seek approval under Nasdaq rules for a $25,000,000 equity line with White Lion Capital, warrants to purchase up to 4,411,764 ADSs plus 117,647 placement‑agent ADSs, and a potential private placement that could be deemed a change of control. The board also asks authority to allot up to USD 20,000 nominal share capital, equivalent to 4,000,000,000,000 ordinary shares (50,000,000 ADSs), and to disapply pre‑emption rights through June 30, 2031. The board unanimously recommends voting in favor of all resolutions.